Reason for request
Inclusion on the list of medicines reimbursed by National Health Insurance and approved for hospital use.
Clinical Benefit
| Substantial |
The actual benefit of OZURDEX 700 μg intravitreal implant in applicator is substantial. |
Clinical Added Value
| minor |
OZURDEX 700 μg intravitreal implant in applicator offers a minor improvement in actual benefit (IAB IV) in the management of the treatment of macular oedema and oedema following either branch retinal vein occlusion or central retinal vein occlusion. |
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
nTfZKwRgYtdJa5eZ
